Case Study

92% Accuracy In Early Parkinson's Classification

Source: Clinical ink
Clinical Data

A common primary endpoint in pivotal clinical studies of Parkinson’s Disease (PD) is a rating scale completed in part by patients/caregivers and in part by clinicians. While this traditional assessment, the Unified Parkinson’s Disease Rating Scale (UPDRS), is qualified by regulators, it is an imperfect stand-alone tool for characterizing disease, as it is episodic and can be subjective. Drug developers and clinicians have long sought biomarkers than can generate more objective, richer, quantitative metrics of disease probability, severity, and risk for progression.

The Clinical ink team partnered with the University of Rochester and two bio-pharmaceutical companies on WATCH-PD to explore the viability of consumer grade digital health technologies (DHTs) as a method for capturing patient data to complement traditional in-clinic measures. 

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader